Asunercept

Active substance
Asunercept
Domain
Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen
New medicine (specialité)
Main indication
Brain cancer
Extended indication
Treatment of recurrent glioblastoma

1. Product

Manufacturer
Apogenix
Mechanism of action
Immunostimulation
Route of administration
Intravenous
Therapeutical formulation
Intravenous drip
Budgetting framework
Intermural (MSZ)
Additional comments
Asunercept works by attaching to a protein known as the CD95 ligand, which triggers a natural process that leads to cell death (apoptosis).

2. Registration

Registration route
Centralised (EMA)
Type of trajectory
Accelerated assessment
Particularity
New medicine with Priority Medicines (PRIME)
Orphan drug
Yes
Registration phase
Clinical trials

3. Therapeutic value

Therapeutic value
No judgement
Duration of treatment
Not found
Additional comments
IV 800 mg weekelijks

4. Expected patient volume per year

Patient volume

< 500

Market share is generally not included unless otherwise stated.

References
NKR; expertopinie
Additional comments
In Nederland zijn er jaarlijks ongeveer 1.100 patiënten met de diagnose glioma waarbij er ongeveer 800 de diagnose glioblastoma krijgen. Hiervan worden er tussen de 60-70% primair behandeld met chemoradiatie. Meer dan 90% van de glioblastoma's zijn recurrent. Er zullen dus maximaal 500 patiënten mogelijk in aanmerking komen voor deze behandeling.

5. Expected cost per patient per year

There is currently nothing known about the expected cost.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

Indication extension
No

9. Other information

There is currently no futher information available.